文献速递肝病

Emricasan(IDN-6556)降低代偿性肝硬化合并严重门静脉高压患者的门静脉压力

Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension.
PubMed 文献 · Hepatology · 2018-11-26

这项多中心、开放标签探索性研究纳入23例代偿性肝硬化合并门静脉高压(肝静脉压力梯度>5 mmHg)患者,给予Emricasan 25 mg每日两次共28天。总体肝静脉压力梯度无显著变化,但在严重门静脉高压(≥12 mmHg)患者中显著下降,且耐受性良好。

要点

  • Emricasan 25 mg每日两次治疗28天,总体肝静脉压力梯度无显著变化。
  • 严重门静脉高压(肝静脉压力梯度≥12 mmHg)患者中肝静脉压力梯度显著下降。
  • 天冬氨酸氨基转移酶和丙氨酸氨基转移酶在总体及严重门静脉高压患者中均显著下降。

核心结论

  • Emricasan治疗28天可降低代偿性肝硬化合并严重门静脉高压患者的肝静脉压力梯度,可能对门静脉血流有影响,天冬氨酸氨基转移酶和丙氨酸氨基转移酶同步下降提示肝内抗炎效应。

研究设计与样本

  • 多中心、开放标签探索性研究,纳入23例代偿性肝硬化合并门静脉高压(肝静脉压力梯度>5 mmHg)患者,给予Emricasan 25 mg每日两次共28天。
  • 肝静脉压力梯度测量标准化,治疗前后各进行一次,所有描记图由单一专家判读。

主要发现

  • 中位年龄59岁(范围49-80),男性占70%,肝硬化病因包括非酒精性脂肪性肝炎和丙型肝炎病毒,Child A级占87%,终末期肝病模型评分中位数8分(范围6-15)。
  • 12例存在严重门静脉高压(肝静脉压力梯度≥12 mmHg)。
  • 总体肝静脉压力梯度无显著变化(平均[标准差] -1.1[4.57] mmHg)。
  • 严重门静脉高压患者肝静脉压力梯度显著下降(平均[标准差] -3.7[4.05] mmHg;P=0.003),其中4/12例下降≥20%,8/12例下降≥10%,2/12例肝静脉压力梯度降至12 mmHg以下。
  • 血压和心率无显著变化;天冬氨酸氨基转移酶和丙氨酸氨基转移酶在总体及严重门静脉高压患者中均显著下降;血清切割型细胞角蛋白18和caspase-3/7显著下降。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Caspases play a central role in apoptosis, inflammation, and fibrosis. They produce hemodynamically active, proinflammatory microparticles that cause intrahepatic inflammation, vasoconstriction, and extrahepatic splanchnic vasodilation. Emricasan is a pan-caspase inhibitor that lowers portal hypertension (PH) and improves survival in murine models of cirrhosis. This exploratory study assessed whether emricasan lowers PH in patients with compensated cirrhosis. This multicenter, open-label study enrolled 23 subjects with compensated cirrhosis and PH (hepatic vein pressure gradient [HVPG] >5 mm Hg). Emricasan 25 mg twice daily was given for 28 days. HVPG measurements were standardized and performed before and after emricasan. A single expert read all HVPG tracings. Median age was 59 (range 49-80); 70% were male. Cirrhosis etiologies were nonalcoholic steatohepatitis and hepatitis C virus. Subjects were Child class A (87%) with a median Model for End-Stage Liver Disease score of 8 (range 6-15). Twelve had severe PH (HVPG ≥12 mm Hg). Overall, there was no significant change in HVPG after emricasan (mean [standard deviation, SD] -1.1 [4.57] mm Hg). HVPG decreased significantly (mean [SD] -3.7[4.05] mm Hg; P = 0.003) in those with severe PH: 4/12 had a ≥20% decrease, 8/12 had a ≥10% decrease, and 2/12 HVPG decreased below 12 mm Hg. There were no significant changes in blood pressure or heart rate. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) decreased significantly in the entire group and in those with severe PH. Serum cleaved cytokeratin 18 and caspase-3/7 decreased significantly. Emricasan was well tolerated. One subject discontinued for nonserious adverse events. Conclusion: Emricasan administered for 28 days decreased HVPG in patients with compensated cirrhosis and severe PH; an effect upon portal venous inflow is likely, and concomitant decreases in AST/ALT suggest an intrahepatic anti-inflammatory effect.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Garcia-Tsao G, Fuchs M, Shiffman M, et al. Emricasan (IDN-6556) Lowers Portal Pressure in Patients With Compensated Cirrhosis and Severe Portal Hypertension. Hepatology. 2018. PMID: 30063802. doi:10.1002/hep.30199

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。